PL356559A1 - 2-Guanidyno-4-arylochinazoliny jako inhibitory NHE-3 - Google Patents

2-Guanidyno-4-arylochinazoliny jako inhibitory NHE-3

Info

Publication number
PL356559A1
PL356559A1 PL01356559A PL35655901A PL356559A1 PL 356559 A1 PL356559 A1 PL 356559A1 PL 01356559 A PL01356559 A PL 01356559A PL 35655901 A PL35655901 A PL 35655901A PL 356559 A1 PL356559 A1 PL 356559A1
Authority
PL
Poland
Prior art keywords
arylchinazolines
nhe
guanidino
inhibitors
Prior art date
Application number
PL01356559A
Other languages
English (en)
Inventor
Rolf Gericke
Norbert Beier
Claudia Wilm
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL356559A1 publication Critical patent/PL356559A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL01356559A 2000-04-18 2001-03-22 2-Guanidyno-4-arylochinazoliny jako inhibitory NHE-3 PL356559A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10019062A DE10019062A1 (de) 2000-04-18 2000-04-18 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
PCT/EP2001/003281 WO2001079186A1 (de) 2000-04-18 2001-03-22 2-guanidino-4-aryl-chinazoline als nhe-3-inhibitoren

Publications (1)

Publication Number Publication Date
PL356559A1 true PL356559A1 (pl) 2004-06-28

Family

ID=7639090

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01356559A PL356559A1 (pl) 2000-04-18 2001-03-22 2-Guanidyno-4-arylochinazoliny jako inhibitory NHE-3

Country Status (18)

Country Link
US (1) US20040224965A1 (pl)
EP (1) EP1274691A1 (pl)
JP (1) JP2004501082A (pl)
KR (1) KR20030011789A (pl)
CN (1) CN1422260A (pl)
AR (1) AR028914A1 (pl)
AU (1) AU2001293373A1 (pl)
BR (1) BR0109867A (pl)
CA (1) CA2406161A1 (pl)
DE (1) DE10019062A1 (pl)
HU (1) HUP0300909A3 (pl)
MX (1) MXPA02010264A (pl)
NO (1) NO20024997D0 (pl)
PL (1) PL356559A1 (pl)
RU (1) RU2002130246A (pl)
SK (1) SK13472002A3 (pl)
WO (1) WO2001079186A1 (pl)
ZA (1) ZA200209274B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10043667A1 (de) * 2000-09-05 2002-03-14 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline
DK1453810T3 (da) * 2001-12-05 2009-07-20 Sanofi Aventis Deutschland Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
US6911453B2 (en) 2001-12-05 2005-06-28 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
DE10161767A1 (de) * 2001-12-15 2003-06-26 Merck Patent Gmbh 2-Guanidino-4-heterocyclyl-chinazoline
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
US20030187045A1 (en) 2001-12-21 2003-10-02 Uwe Heinelt Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic
US6703405B2 (en) 2001-12-22 2004-03-09 Aventis Pharma Deutschland Gmbh Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them
DE10163914A1 (de) * 2001-12-22 2003-07-03 Aventis Pharma Gmbh Substituierte 4-Phenyltetrahydroisochinolinium-Salze, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE10163992A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh 4-Aryl-chinazoline
US7049333B2 (en) * 2002-06-04 2006-05-23 Sanofi-Aventis Deutschland Gmbh Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis
US20050054705A1 (en) 2003-02-04 2005-03-10 Aventis Pharma Deutschland Gmbh N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
DE10304374A1 (de) 2003-02-04 2004-08-05 Aventis Pharma Deutschland Gmbh Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10341240A1 (de) 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE102005001411A1 (de) 2005-01-12 2006-07-27 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
ATE479679T1 (de) 2007-06-28 2010-09-15 Sanofi Aventis Us Llc Verfahren zur herstellung von n-(2-chlor-4-methyl-3-thienyl)-1h-benzimidazol- 2-amin hydrochlorid und zwischenprodukte dafür
EP2342178B1 (en) 2008-09-02 2016-09-28 Sanofi Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
CN103819403B (zh) 2008-12-31 2017-01-04 阿德利克斯公司 用于治疗与体液潴留或盐超负荷有关的病症和胃肠道病症的化合物和方法
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US20120088737A2 (en) * 2009-10-02 2012-04-12 Ajinomoto Co., Inc Novel acyl guanidine derivatives
RU2015107019A (ru) 2012-08-21 2016-10-10 Эрделикс Инк. Соединения и способы для ингибирования nhe-опосредованного антипорта в лечении расстройств, ассоциированных с задержкой жидкости или солевой перегрузкой и заболеваний желудочно-кишечного тракта
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN105392483B (zh) 2013-04-12 2019-03-15 阿德利克斯公司 用于抑制磷酸盐转运的nhe3结合化合物和方法
WO2016013657A1 (ja) 2014-07-25 2016-01-28 大正製薬株式会社 ヘテロアリールで置換されたフェニルテトラヒドロイソキノリン化合物
KR20240090875A (ko) 2017-01-09 2024-06-21 알데릭스, 인코포레이티드 위장관 장애를 치료하는 데 유용한 화합물
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CN111386279A (zh) 2017-08-04 2020-07-07 阿德利克斯股份有限公司 用于治疗高钾血症的甘草次酸衍生物
JP7735185B2 (ja) 2019-02-07 2025-09-08 アルデリックス, インコーポレイテッド 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス, インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3131187A (en) * 1964-04-28 Certain z-guantoino-x-aryl-quinazolines

Also Published As

Publication number Publication date
CN1422260A (zh) 2003-06-04
NO20024997L (no) 2002-10-17
MXPA02010264A (es) 2003-04-25
HUP0300909A3 (en) 2004-01-28
EP1274691A1 (de) 2003-01-15
WO2001079186A1 (de) 2001-10-25
DE10019062A1 (de) 2001-10-25
US20040224965A1 (en) 2004-11-11
RU2002130246A (ru) 2004-03-27
SK13472002A3 (sk) 2003-02-04
JP2004501082A (ja) 2004-01-15
BR0109867A (pt) 2003-06-03
KR20030011789A (ko) 2003-02-11
NO20024997D0 (no) 2002-10-17
CA2406161A1 (en) 2002-10-16
AR028914A1 (es) 2003-05-28
ZA200209274B (en) 2004-02-16
AU2001293373A1 (en) 2001-10-30
HUP0300909A2 (hu) 2003-10-28

Similar Documents

Publication Publication Date Title
AU2001293373A1 (en) 2-guanidino-4-arylchinazolines as NHE-3 inhibitors
IL156064A0 (en) Vla-4 inhibitors
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
GB9900416D0 (en) Inhibitors
IL151104A0 (en) Kinase inhibitors
AP2002002593A0 (en) Protease inhibitors
PL369855A1 (pl) 4-arylochinazoliny i ich zastosowanie jako inhibitorów NHE-3
EP1324759A4 (en) NF - G (K) B INHIBITORS
AU6381701A (en) Bisamidino compounds as nhe-3 inhibitors
PL355097A1 (pl) Pochodne bifenylu jako inhibitory NHE-3
AU4217201A (en) Tri-aryl-substituted-ethane pde4 inhibitors
EP1307204A4 (en) PROTEASES INHIBITORS
GB0030284D0 (en) Enzyme inhibitors
GB0018164D0 (en) Corrosion inhibitors
EP1153022A4 (en) PROTEASE INHIBITORS
EP1278502A4 (en) PROTEASE INHIBITORS
GB2359500B (en) Corrosion inhibitors
GB2389113B (en) B-secretase inhibitor
GB0229613D0 (en) Biocatalyst inhibitors
GB0014861D0 (en) Novel telomerase inhibitors
GB0021193D0 (en) Inhibitors
GB0015996D0 (en) Inhibitors
GB0029730D0 (en) Inhibitors
GB0029733D0 (en) Inhibitors
GB0000829D0 (en) Growth inhibitor

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)